Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 25, 2026 | June 29, 2026 |
| Eledon Pharmaceuticals, Inc.NVUS · Entity 6160 | Director | July 11, 2019 | July 15, 2019 |
| IMMUNIC, INC.VTL · Entity 6306 | Director | September 12, 2018 | September 14, 2018 |
| ImmunityBio, Inc.IBRX · Entity 3618 | Director | October 02, 2026 | October 06, 2026 |
| Lite Strategy, Inc.MEIP · Entity 7396 | Director | July 05, 2022 | July 07, 2022 |
| Peak Bio, Inc.IGNY · Entity 85431 | Director | January 27, 2021 | January 27, 2021 |
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | Director | June 30, 2021 | July 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 26,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 26,000 · Balance 26,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Eledon Pharmaceuticals, Inc.
Report date July 11, 2019 · Filed July 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2029-07-11 | Direct | 20,000 |
Reported balance
After 2019-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-11 · Grant · Acquired 20,000 · Balance 20,000 |
IMMUNIC, INC.
Report date September 12, 2018 · Filed September 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2018-09-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-09-12 · Sale · Disposed 3,500 · Balance 0 F1: Shares held by Cheryl L. Cohen Trust U/A 04/01/05 Cheryl L. Cohen Trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Cheryl L. Cohen Trust U/A 04/01/05 Cheryl L. Cohen Trustee.
ImmunityBio, Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,309 |
Ending reported balance
After 2026-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 55,979 · Balance 181,365 Row 2 · 2026-10-02 · Sale · Disposed 81,056 · Balance 100,309 F1: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.98 · Expires 2032-06-14 | Direct | 55,979 |
Reported balance
After 2026-10-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-02 · Exercise / conversion · Disposed 55,979 · Balance 55,979 |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026.
Lite Strategy, Inc.
Report date July 05, 2022 · Filed July 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2032-07-05 | Direct | 87,500 |
Reported balance
After 2022-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-05 · Grant · Acquired 87,500 · Balance 87,500 F1: The options will vest in equal monthly installments over twelve months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2031-07-01 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 50,000 F2: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.49 · Expires 2030-07-02 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 50,000 F2: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2030-04-10 | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 30,000 F3: 20,000 options will vest in equal monthly installments over thirty-six months from April 10, 2020 and 10,000 options shall vest in equal monthly installments over twelve months from April 10, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in equal monthly installments over twelve months.
F2: All of such options are presently exercisable.
F3: 20,000 options will vest in equal monthly installments over thirty-six months from April 10, 2020 and 10,000 options shall vest in equal monthly installments over twelve months from April 10, 2020.
Peak Bio, Inc.
Report date January 27, 2021 · Filed January 27, 2021
This filing explicitly reported no securities owned.
Whitehawk Therapeutics, Inc.
Report date June 30, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,160 |
Reported balance
After 2021-06-30 transaction · row 1
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 8,140 · Balance 16,160 F1: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 22:05 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 55,979 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001326110-26-000084 · wk-form4_1791324339.xml · derivative · entry 3 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,979 Underlying: Common Stock · 55,979 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 22:05 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 81,056 | $10.50 | $851,088.00 |
DisclosureSEC source: 0001326110-26-000084 · wk-form4_1791324339.xml · nonDerivative · entry 2 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,309 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 22:05 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 55,979 | $2.98 | $166,817.42 |
DisclosureSEC source: 0001326110-26-000084 · wk-form4_1791324339.xml · nonDerivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 00:26 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 55,979 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001529371-26-000008 · wk-form4_1783383979.xml · derivative · entry 3 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,958 Underlying: Common Stock · 55,979 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 00:26 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 131,210 | $9.50 | $1,246,941.11 |
DisclosureSEC source: 0001529371-26-000008 · wk-form4_1783383979.xml · nonDerivative · entry 2 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,386 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026. F2 · price: Represents the weighted average share price of an aggregate total of 131,210 shares sold in the price range of $9.50 to $9.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 00:26 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 55,979 | $2.98 | $166,817.42 |
DisclosureSEC source: 0001529371-26-000008 · wk-form4_1783383979.xml · nonDerivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 256,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:10 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001529371-26-000005 · form4-06292026_080658.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 00:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 65,600 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001529371-26-000003 · wk-form4_1781136674.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 65,600 shares Expires 2036-06-09 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 22:34 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 162,786 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001326110-25-000093 · wk-form4_1750458881.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,786 Underlying: Common Stock · 162,786 shares Expires 2035-06-18 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:06 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016215 · form4-06092025_080601.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:10 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017153 · form4-06172024_080620.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:49 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 77,633 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001326110-24-000079 · wk-form4_1718318972.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,633 Underlying: Common Stock · 77,633 shares Expires 2034-06-11 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 11, 2025 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:07 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010033 · form4-06202023_080641.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:28 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 158,263 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001326110-23-000088 · wk-form4_1686868079.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,263 Underlying: Common Stock · 158,263 shares Expires 2033-06-13 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:25 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0000899243-22-025709 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2032-07-05 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001493152-22-017153 · ownership.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Stock · 27,200 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: One third vests on the first, second and third anniversaries of the date of grant. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 01:22 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 167,937 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001326110-22-000050 · wf-form4_165534252497788.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,937 Underlying: Common Stock · 167,937 shares Expires 2032-06-14 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2023 or the date immediately preceding the 2023 annual meeting of stockholders. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 22:07 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 14,801 | $10.12 | $149,795.00 |
DisclosureSEC source: 0001209191-21-053210 · doc4.xml · nonDerivative · entry 2 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,617 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 13, 2021. F3 · price: Represents the weighted average share price of an aggregate total of 14,801 shares sold in the price range of $10.02 to $10.27 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 22:07 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 9,976 | $10.00 | $99,807.88 |
DisclosureSEC source: 0001209191-21-053210 · doc4.xml · nonDerivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,418 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 13, 2021. F2 · price: Represents the weighted average share price of an aggregate total of 9,976 shares sold in the price range of $10.00 to $10.02 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 00:42 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 2,133 | $10.03 | $21,389.08 |
DisclosureSEC source: 0001209191-21-052660 · doc4.xml · nonDerivative · entry 2 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,394 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 13, 2021. F3 · price: Represents the weighted average share price of an aggregate total of 2,133 shares sold in the price range of $10.00 to $10.05 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 17, 2021 Filed Aug 20, 2021 00:42 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 43,398 | $10.12 | $439,361.35 |
DisclosureSEC source: 0001209191-21-052660 · doc4.xml · nonDerivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,527 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 13, 2021. F2 · price: Represents the weighted average share price of an aggregate total of 43,398 shares sold in the price range of $10.00 to $10.61 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:56 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001209191-21-045653 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:34 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantCommon Stock | 8,140 | $1.52 | $12,372.80 |
DisclosureSEC source: 0000899243-21-027281 · doc4.xml · nonDerivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,160 F1 · shares: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021. F1 · price: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:42 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0000899243-21-025336 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:34 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 26,064 | $0.00 Strike: $14.91 | $0.00 |
DisclosureSEC source: 0001209191-21-040349 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,064 Underlying: Common Stock · 26,064 shares Expires 2031-06-10 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 10, 2022 or the date immediately preceding the 2022 annual meeting of stockholders. Read SEC document |
| March 31, 2021 Filed Apr 3, 2021 00:30 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantCommon Stock | 8,020 | $1.54 | $12,374.86 |
DisclosureSEC source: 0000899243-21-014676 · doc4.xml · nonDerivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 F1 · shares: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended March 31, 2021. F1 · price: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended March 31, 2021. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 02:35 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 17,857 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000899243-21-004893 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,857 Underlying: Common Stock · 17,857 shares Expires 2031-02-01 F1 · derivative.exercise_date: Options shall vest in four equal quarterly installments beginning on February 1, 2021. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 23:10 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 30,000 | $9.96 | $298,785.00 |
DisclosureSEC source: 0001209191-20-046675 · doc4.xml · nonDerivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,925 F1 · kind: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F2 · price: Represents the weighted average share price of an aggregate total of 30,000 shares sold in the price range of $9.91 to $9.99 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 16:30 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0000899243-20-018597 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-07-02 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:40 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 52,144 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0000899243-20-017769 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,144 Underlying: Common Stock · 52,144 shares Expires 2030-06-24 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 22:20 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001209191-20-036032 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 10, 2021 or the date immediately preceding the 2021 annual meeting of stockholders. Read SEC document |
| April 10, 2020 Filed Apr 14, 2020 21:17 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0000899243-20-010723 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-04-10 F1 · derivative.exercise_date: 20,000 options will vest in equal monthly installments over thirty-six months from April 10, 2020 and 10,000 options shall vest in equal monthly installments over twelve months from April 10, 2020. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:05 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0000899243-19-019597 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-07-11 Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 21:25 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-19-017438 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2029-06-18 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 20:38 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantCommon Stock | 300,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035573 · doc4.xml · nonDerivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,925 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · shares: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) 1/3 of the RSUs shall vest annually beginning on June 6, 2020 Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 20:08 UTC | IMMUNIC, INC. VTL · Entity 6306 | SaleCommon Stock | 3,500 | $0.55 | $1,925.00 |
DisclosureSEC source: 0001280776-18-000085 · wf-form4_153695571919596.xml · nonDerivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · ownership.nature: Shares held by Cheryl L. Cohen Trust U/A 04/01/05 Cheryl L. Cohen Trustee. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:54 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 42,800 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017743 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,800 Underlying: Common Stock · 42,800 shares Expires 2028-06-20 F1 · derivative.exercise_date: Options shall vest annually over three years from the Grant Date, subject to director's continued service on the Board at such time. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 21:54 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 9,100 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0000899243-18-016655 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2028-06-13 Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:09 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 29,538 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001280776-18-000043 · wf-form4_152727894752915.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,538 Underlying: Common Stock · 29,538 shares Expires 2028-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 20:05 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0000899243-17-017762 · doc4.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-06-30 F1 · derivative.exercise_date: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017. Read SEC document |
| May 23, 2017 Filed May 25, 2017 21:27 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 45,022 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-17-000044 · wf-form4_149574762511530.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,022 Underlying: Common Stock · 45,022 shares Expires 2027-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from May 23, 2017 or the day prior to the Company's 2018 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.